Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 139  
This article has been cited by
1Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer
Dominic Bagguley,Sean Ong,James P Buteau,Sam Koschel,Nattakorn Dhiantravan,Michael S Hofman,Louise Emmett,Declan G Murphy,Nathan Lawrentschuk
Future Oncology.2021;17(17)2225
[DOI]
2Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer
Nasim Vahidfar,Maryam Fallahpoor,Saeed Farzanehfar,Ghasemali Divband,Hojjat Ahmadzadehfar
Journal of Radioanalytical and Nuclear Chemistry.2019;322(2)237
[DOI]
3A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
Manoj Gupta,G. Karthikeyan,P. S. Choudhury,Venkata Pradeep Babu Koyyala,Manish Sharma,Parveen Jain,Vineet Talwar,Amitabh Singh,Sudhir Rawal
Cancer Investigation.2020;38(8-9)486
[DOI]
4Neutron-activated theranostic radionuclides for nuclear medicine
Hun Yee Tan,Chai Hong Yeong,Yin How Wong,Molly McKenzie,Azahari Kasbollah,Mohamad Nazri Md. Shah,Alan Christopher Perkins
Nuclear Medicine and Biology.2020;90-91(8-9)55
[DOI]
5Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
Finn Edler von Eyben,Glenn Bauman,Rie von Eyben,Kambiz Rahbar,Cigdem Soydal,Alexander R. Haug,Irene Virgolini,Harshad Kulkarni,Richard Baum,Giovanni Paganelli
International Journal of Molecular Sciences.2020;21(23)9054
[DOI]
6Bench-to-Bedside Theranostics in Nuclear Medicine
Narges Jokar,Majid Assadi,Anna Yordanova,Hojjat Ahmadzadehfar
Current Pharmaceutical Design.2020;26(31)3804
[DOI]
7Theranostic approaches in nuclear medicine: current status and future prospects
Luca Filippi,Agostino Chiaravalloti,Orazio Schillaci,Roberto Cianni,Oreste Bagni
Expert Review of Medical Devices.2020;17(4)331
[DOI]
8A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile
Srikanth Boinapally,Hye-Hyun Ahn,Bei Cheng,Mary Brummet,Hwanhee Nam,Kathleen L. Gabrielson,Sangeeta R. Banerjee,Il Minn,Martin G. Pomper
Scientific Reports.2021;11(1)331
[DOI]
9Precision Medicine Approach in Prostate Cancer
Majid Assadi,Narges Jokar,Mojtaba Ghasemi,Iraj Nabipour,Ali Gholamrezanezhad,Hojjat Ahmadzadehfar
Current Pharmaceutical Design.2020;26(31)3783
[DOI]
10Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Michael Sun,Muhammad O Niaz,Adlai Nelson,Myrto Skafida,Muhammad J Niaz
Cureus.2020;26(31)3783
[DOI]
11Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
Hojjat Ahmadzadehfar,Kambiz Rahbar,Richard P. Baum,Robert Seifert,Katharina Kessel,Martin Bögemann,Harshad R Kulkarni,Jingjing Zhang,Carolin Gerke,Rolf Fimmers,Clemens Kratochwil,Hendrik Rathke,Harun Ilhan,Johanna Maffey-Steffan,Mike Sathekge,Levent Kabasakal,Francisco Osvaldo Garcia-Perez,Kalevi Kairemo,Masha Maharaj,Diana Paez,Irene Virgolini
European Journal of Nuclear Medicine and Molecular Imaging.2021;48(1)113
[DOI]
12Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects
Valentina Fuoco,Giovanni Argiroffi,Stefania Mazzaglia,Alice Lorenzoni,Valentina Guadalupi,Andrea Franza,Federica Scalorbi,Gianluca Aliberti,Carlo Chiesa,Giuseppe Procopio,Ettore Seregni,Marco Maccauro
Tumori Journal.2021;48(1)030089162110377
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal